Empathy is critical to young children’s socioemotional development and deficient levels characterize a severe and pervasive type of Conduct Disorder (i.e., with limited prosocial emotions). With the emergence of novel, targeted early interventions to treat this psychopathology, the critical limitations of existing parent-report empathy measures reveal their unsuitability for assessing empathy levels and outcomes in young children. The present study aimed to develop a reliable and comprehensive parent-rated empathy scale for young children. This was accomplished by first generating a large list of empathy items sourced from both preexisting empathy measures and from statements made by parents during a clinical interview about their young child’s empathy. Second, this item set was refined using exploratory factor analysis of item scores from parents of children aged 2 to 8 years (56.6% male), recruited online using Amazon’s Mechanical Turk. A five-factor solution provided the best fit to the data: Attention to Others’ Emotions, Personal Distress (i.e., Emotional Contagion/Affective Empathy), Personal Distress–Fictional Characters, Prosocial Behavior, and Sympathy. Total and subscale scores on the new “Measure of Empathy in Early Childhood” (MEEC) were internally consistent. Finally, this five-factor structure was tested using confirmatory factor analysis and model fit was adequate. With further research into the validity of MEEC scores, this new rater-based empathy measure for young children may hold promise for assessing empathy in early childhood and advancing research into the origins of empathy and empathy-related disorders.

No abstract

Open label placebos (OLPs) appear generally efficacious among clinical samples, but the empirical evidence regarding their use in non‐clinical and sub‐clinical samples, as well as when administered independent of a convincing rationale, is mixed. Healthy participants (N = 102) were randomised to either a 6‐day course of OLP pills with information provision (OLP‐plus: N = 35), without information provision (OLP‐only: N = 35), or no‐treatment control group (N = 32). OLP pills were described as enhancing physical (symptoms and sleep) and psychological (positive and negative emotional) well‐being. Well‐being was assessed at baseline and on Day 6. Expectancies and adherence were measured. OLP administration interacted with baseline well‐being. The OLP‐plus group demonstrated increased well‐being on all outcomes other than positive emotions, but only when they reported decreased baseline well‐being. OLP‐only and control groups did not differ. The OLP‐plus group demonstrated elevated expectancies, that mediated the OLP effect on physical symptoms relative to control, but only when well‐being was lower than average at baseline (i.e. moderated‐mediation). Results demonstrate the importance of information provided with OLPs. The moderating effect of baseline outcomes may reconcile inconsistent results regarding clinical and non‐clinical samples. Accounting for baseline symptoms in non‐clinical and sub‐clinical samples is likely to enhance our understanding of when OLPs are effective.